started · updated
Ghana launches policy to reduce medicine import reliance
Ghana has unveiled the Ghana Pharmaceutical Manufacturing Policy (GPMP) to address the nation's 70% dependence on imported medicines. Approved by Cabinet, the policy aims to establish a domestic pharmaceutical ecosystem by addressing obstacles such as infrastructure, raw materials, and access to finance.
A central component of the initiative is the creation of a pharmaceutical hub or park. This hub is intended to consolidate manufacturers, research facilities, and input suppliers. Phase 2 of the plan, proposed for the Central Region, focuses on the production of active pharmaceutical ingredients, herbal medicines, and raw materials like pharmaceutical-grade corn starch and ethyl alcohol.
In support of these industrial goals, research projects are currently underway to advance locally produced treatments. The Centre for Plant Medicine Research, in partnership with the Dodowa Health Research Centre and Atlantic Life Sciences Ltd., is conducting clinical trials for URO 500, a herbal medicine for prostate health. Additionally, researchers are testing the stability of a locally manufactured snake venom antiserum. These projects are part of the PharmaVax Ghana initiative, supported by GIZ, the National Vaccine Institute-Ghana, the European Union, and Germany’s Federal Ministry for Economic Cooperation and Development.
Entities
Centre for Plant Medicine Research · Deutsche Gesellschaft für Internationale Zusammenarbeit · European Union · Ghana · National Vaccine Institute-Ghana